Answers are grounded in this paper and cite their sources.
Uncovers the synergy of apatinib and PD-L1 inhibition in reducing tumor growth in breast cancer, suggesting a potential new treatment approach.
Studies in breast cancer have demonstrated that apatinib exhibits both antiangiogenic and antitumor effects, while PD-L1 inhibitors have similarly shown meaningful clinical benefit. Building upon these observations, this study evaluated the potential synergistic antitumor effects of combining apatinib with a PD-L1 inhibitor and examined the mechanistic basis for their interaction in breast cancer. Notably, we found that this regimen could significantly suppress the proliferation, migration, and invasion of MCF-7 and MDA-MB-231 cells, and promote cell apoptosis. In addition, the levels of p-ERK, NF-κB, and Slug were markedly reduced in vitro. Collectively, these findings support the potential clinical utility of combining apatinib and PD-L1 inhibition, as evidenced by consistent in vitro and in vivo synergy.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: